Serum pepsinogen: A potential non-invasive screening method for moderate and severe atrophic gastritis among an asian population

Long, Nguyen Cong; Dao, Tien Xuan; Phi, Ngan Thi Thuy; Phuong, Nguyen The; Tuyen, Pham Van; Vu, Khanh Truong

doi:10.1016/j.amsu.2022.103844

Cited by 4 publications

(7 citation statements)

References 28 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The diagnostic value of PG testing has been assessed in several studies using different methods (enzyme-linked immunosorbent assay, ELISA; Chemiluminescent Immunoassay, CLEIA), with a different cut-off value for each method and adjusted for different population/ethnicity [30][31][32][33][34][35][36][37][38] (Table 1). The role of PG serology in atrophic gastritis has been underlined in several international recommendations: MAPS I and II consensus stated that serum pepsinogen levels can predict extensive CAG.…”

Section: Blood Biomarkers 131 Validated and Commercially Available Bi...mentioning

confidence: 99%

“…Presented outcomes reflect a diagnosis of CAG based on histopathological examination. Still, PGI and PGI/II also showed similar outcomes in the endoscopic diagnosis of atrophy using the Kimura–Takemoto classification [ 32 , 37 , 39 ]. Also, PG testing is effective in the prediction of atrophy based on the origin of gastritis.…”

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Non-Invasive Markers for the Detection of Gastric Precancerous Conditions

Romańczyk,

Osmola,

Link

et al. 2024

Cancers

View full text Add to dashboard Cite

Gastric cancer (GC) is still one of the most prevalent cancers worldwide, with a high mortality rate, despite improvements in diagnostic and therapeutic strategies. To diminish the GC burden, a modification of the current diagnostic paradigm, and especially endoscopic diagnosis of symptomatic individuals, is necessary. In this review article, we present a broad review and the current knowledge status on serum biomarkers, including pepsinogens, gastrin, Gastropanel®, autoantibodies, and novel biomarkers, allowing us to estimate the risk of gastric precancerous conditions (GPC)—atrophic gastritis and gastric intestinal metaplasia. The aim of the article is to emphasize the role of non-invasive testing in GC prevention. This comprehensive review describes the pathophysiological background of investigated biomarkers, their status and performance based on available data, as well as their clinical applicability. We point out future perspectives of non-invasive testing and possible new biomarkers opportunities.

show abstract

Section: Blood Biomarkers 131 Validated and Commercially Available Bi...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Non-Invasive Markers for the Detection of Gastric Precancerous Conditions

Romańczyk,

Osmola,

Link

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Currently, biomarkers including CEA, CA19‐9, and CA72‐4 are frequently utilized in the detection of patients with GC, although their diagnosis is somewhat limited due to their low sensitivity or specificity 3 . Additionally, PG I, PG II, and PG I/II have less usefulness in the diagnosis of GC 4 . Finding new biomarkers for the early diagnosis, therapy, and prognostic evaluation of GC becomes critical and necessary.…”

Section: Introductionmentioning

confidence: 99%

“… 3 Additionally, PG I, PG II, and PG I/II have less usefulness in the diagnosis of GC. 4 Finding new biomarkers for the early diagnosis, therapy, and prognostic evaluation of GC becomes critical and necessary.…”

Section: Introductionmentioning

confidence: 99%

Serum circular RNA hsa_circ_0000702 as a novel biomarker for diagnosis of gastric cancer

Yuan

Fang

Mao

et al. 2023

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

Potential diagnostic, prognostic, and predictive biomarkers of gastric cancer

Mohammed,

Gizaw,

Degef

2024

Health Science Reports

View full text Add to dashboard Cite

BackgroundGastric cancer (GC), a malignant epithelial tumor, is the fourth leading cause of cancer‐related death worldwide. Therapeutic strategies for GC, despite the biggest challenges, can significantly improve survival rates through early detection and effective screening methods.AimTo provide brief information on the necessity of multiple specific diagnostic, prognostic, and predictive markers for GC.MethodsThis review was conducted using a variety of search engines, including PubMed Central, Scopus, Web of Science, Google Scholar, and others.ResultsSome potential biomarkers that provide essential information include circulating tumor cells (CTCs), DNA methylation, claudin 18.2, fibroblast growth factor receptor 2 (FGFR2), long noncoding RNAs (lncRNAs), cell‐free DNA (cfDNA), microRNAs, and serum pepsinogens.ConclusionMultiple tumor markers are essential for screening, tumor identification, staging, prognostic assessment, and monitoring recurrence after therapy due to the absence of a single tumor indicator for diagnosing, prognosticating, and predicting GC.

show abstract

Serum pepsinogen: A potential non-invasive screening method for moderate and severe atrophic gastritis among an asian population

Cited by 4 publications

References 28 publications

Non-Invasive Markers for the Detection of Gastric Precancerous Conditions

Non-Invasive Markers for the Detection of Gastric Precancerous Conditions

Serum circular RNA hsa_circ_0000702 as a novel biomarker for diagnosis of gastric cancer

Potential diagnostic, prognostic, and predictive biomarkers of gastric cancer

Contact Info

Product

Resources

About